ReviewGut2020
Advances in non-invasive assessment of hepatic fibrosis.
Review in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
190 citing papers in PubMed, 4 syntheses or guidelines pooled it, 312 citations in OpenAlex.
- Short-Term Impact of Endoscopic Gastric Remodeling in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.Obesity surgery · 2026Pooled it
- AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.Gastroenterology · 2022Guideline
- Alcohol Consumption and Risk of Liver Fibrosis in People Living With HIV: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.Hepatology international · 2021Guideline
- Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study.Journal of diabetes and its complications · 2023Trial
- Spectral CT predicts initial bleeding risk in cirrhotic patients with esophagogastric varices.Abdominal radiology (New York) · 2026Article
- Comparing the Effect of Changes in Alcohol Intake on Liver Fibrosis Risk Scores Among Patients With Two Distinct Types of Steatotic Liver Disease.Journal of gastroenterology and hepatology · 2026Observational
- Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography.Hepatology communications · 2026Article
- Article
- National guideline for hepatitis B elimination in Thailand: a decentralized health system model for expanding diagnosis and treatment.Hepatology international · 2026Article
- Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Review
- Chronic Liver Disease: Assessing Inflammation and Fibrosis Using Three-Dimensional MR Elastography With Same-Day Biopsy in a Prospective Cohort.Journal of magnetic resonance imaging : JMRI · 2026Article
- Association Between Early and Long-Term Changes in Liver Stiffness in Patients with MASLD Undergoing Serial Magnetic Resonance Elastography.Diagnostics (Basel, Switzerland) · 2026Article
- Differentiating advanced from non-advanced hepatic fibrosis: a hybrid deep learning-radiomics model leveraging synthetic contrast-enhanced CT from CycleGAN.Abdominal radiology (New York) · 2026Article
- Mechanisms and reversal strategies of liver fibrosis: from regulation of cell fate to clinical translation.Journal of translational medicine · 2026Review
- Multimodal data analysis reveals asynchronous aging dynamics across female reproductive organs.Nature aging · 2026Article
- Tongue Image Analysis and Clinical Data Fusion: A Novel Approach for Non-invasive Diagnosis of Metabolic Dysfunction-associated Fatty Liver Disease.Journal of clinical and translational hepatology · 2026Article
- Optimized CAP cut-offs for metabolic dysfunction associated steatotic liver disease in patients living with obesity: a large biopsy-based prospective study.Scientific reports · 2026Article
- Article
- Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome.American journal of preventive cardiology · 2026Article
130 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Liver fibrosis should be assessed in all individuals with chronic liver disease as it predicts the risk of future liver-related morbidity and thus need for treatment, monitoring and surveillance. Non-invasive fibrosis tests (NITs) overcome many limitations of liver biopsy and are now routinely incorporated into specialist clinical practice. Simple serum-based tests (eg, Fibrosis Score 4, non-alcoholic fatty liver disease Fibrosis Score) consist of readily available biochemical surrogates and clinical risk factors for liver fibrosis (eg, age and sex). These have been extensively validated across a spectrum of chronic liver diseases, however, tend to be less accurate than more 'complex' serum tests, which incorporate direct measures of fibrogenesis or fibrolysis (eg, hyaluronic acid, N-terminal propeptide of type three collagen). Elastography methods quantify liver stiffness as a marker of fibrosis and are more accurate than simple serum NITs, however, suffer increasing rates of unreliability with increasing obesity. MR elastography appears more accurate than sonographic elastography and is not significantly impacted by obesity but is costly with limited availability. NITs are valuable for excluding advanced fibrosis or cirrhosis, however, are not sufficiently predictive when used in isolation. Combining serum and elastography techniques increases diagnostic accuracy and can be used as screening and confirmatory tests, respectively. Unfortunately, NITs have not yet been demonstrated to accurately reflect fibrosis change in response to treatment, limiting their role in disease monitoring. However, recent studies have demonstrated lipidomic, proteomic and gut microbiome profiles as well as microRNA signatures to be promising techniques for fibrosis assessment in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.